|
|
News for Healthier Living
Structurally guided therapy shows promise for patients with specific EGFR-mutated lung cancer in Phase 1b trial
For patients with EGFR PACC-mutated non-small cell lung cancer (NSCLC), the targeted therapy firmonertinib achieved durable antitumor activity in a Phase 1b trial led by researchers at The University of Texas MD Anderson Cancer Center, supporting an approach to selecting treatments based on the structural features of uncommon EGFR mutations.
October 16, 2026
October 29 2026October 28 2026October 27 2026October 26 2026October 25 2026October 24 2026October 23 2026October 22 2026October 21 2026October 20 2026October 19 2026October 18 2026October 17 2026October 16 2026
|
|
|
|
|